Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
64,967,756
-
Total 13F shares
-
18,360,151
-
Share change
-
+463,653
-
Total reported value
-
$378,973,000
-
Price per share
-
$20.64
-
Number of holders
-
53
-
Value change
-
+$7,774,419
-
Number of buys
-
29
-
Number of sells
-
17
Institutional Holders of Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) as of Q4 2020
As of 31 Dec 2020,
Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) was held by
53 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,360,151 shares.
The largest 10 holders included
Novo Holdings A/S, NEA Management Company, LLC, Sofinnova Investments, Inc., RA CAPITAL MANAGEMENT, L.P., Pivotal bioVenture Partners Investment Advisor LLC, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), CHI Advisors LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Rock Springs Capital Management LP, and BlackRock Inc..
This page lists
53
institutional shareholders reporting positions in this security
for the Q4 2020 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.